Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (Q39311439)

28 October 2017

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (English)

1 reference

28 October 2017

0 references

15

1 reference

PubMed publication ID

10 September 2017

1

Alexander M M Eggermont

0 references

Caroline Robert

8

Caroline Robert

0 references

Jean-Jacques Grob

3

Jean-Jacques Grob

0 references

Virginia Ferraresi

Virginia Ferraresi

12

0 references

Lars Bastholt

Lars Bastholt

16

0 references

Paolo Antonio Ascierto

9

Paolo A Ascierto

1 reference

28 October 2017

5

Jedd D Wolchok

1 reference

28 October 2017

26

Stefan Suciu

1 reference

28 October 2017

22

F Stephen Hodi

1 reference

28 October 2017

4

Reinhard Dummer

1 reference

28 October 2017

20

Axel Hauschild

1 reference

28 October 2017

Vanna Chiarion-Sileni

2

1 reference

28 October 2017

Henrik Schmidt

6

1 reference

28 October 2017

Omid Hamid

7

1 reference

28 October 2017

Jon M Richards

10

1 reference

28 October 2017

Céleste Lebbé

11

1 reference

28 October 2017

Michael Smylie

13

1 reference

28 October 2017

Jeffrey S Weber

14

1 reference

28 October 2017

Laurent Mortier

17

1 reference

28 October 2017

Luc Thomas

18

1 reference

28 October 2017

Saad Tahir

19

1 reference

28 October 2017

Jessica C Hassel

21

1 reference

28 October 2017

Corina Taitt

23

1 reference

28 October 2017

Veerle de Pril

24

1 reference

28 October 2017

Gaetan de Schaetzen

25

1 reference

28 October 2017

Alessandro Testori

27

1 reference

28 October 2017

language of work or name

English

0 references

publication date

7 October 2016

1 reference

The New England Journal of Medicine

28 October 2017

1 reference

28 October 2017

375

1 reference

28 October 2017

19

1 reference

28 October 2017

1845-1855

1 reference

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

28 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensi

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Final version of 2009 AJCC melanoma staging and classification

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648545

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

4 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27717298

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1611299

1 reference

28 October 2017

1 reference

28 October 2017

PubMed publication ID

27717298

1 reference